STAT5 triggers BCR-ABL1 mutation by mediating ROS production in chronic myeloid leukaemia
Metrics: PDF 2338 views | HTML 1936 views | ?
Wolfgang Warsch1,*, Eva Grundschober1,*, Angelika Berger1, Lars Gille1, Sabine Cerny-Reiterer2,3, Anca-Sarmiza Tigan1, Andrea Hoelbl-Kovacic1, Peter Valent2,3, Richard Moriggl4 & Veronika Sexl1
1 Institute of Pharmacology and Toxicology, Veterinary University Vienna, Veterinaerplatz 1, 1210 Vienna, Austria
2 Department of Internal Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna (MUV), Austria
3 Ludwig Boltzmann Cluster Oncology, Vienna, Austria
4 Ludwig Boltzmann Institute for Cancer Research (LBI-CR), Vienna, Austria
* Denotes equal contribution
Veronika Sexl, email:
Keywords: BCR-ABL1, Chronic Myeloid Leukaemia, Reactive Oxygen Species, STAT5, mutation
Received: December 29, 2012, Accepted: December 31, 2012, Published: December 31, 2012
We recently reported that chronic myeloid leukaemia (CML) patients harbour high levels of STAT5 when they progress to advanced phases of disease. Advanced disease is characterized by an increased incidence of BCR-ABL1 mutations. We now describe a highly significant correlation between STAT5 expression and the incidence of BCR-ABL1 mutations in primary CML. Forced expression of STAT5 in murine BCR-ABL1 transformed cells sufficed to enhance the production of reactive oxygen species (ROS) and to trigger DNA damage. STAT5-mediated ROS production is independent of JAK2 but requires concomitant BCR-ABL1 signalling as forced STAT5 expression in untransformed BCR-ABL1 negative cells has no impact on ROS levels. Only within the context of a BCR-ABL1 positive cell does STAT5 transcriptionally regulate a target gene or set of genes that causes the enhanced ROS production. Our study suggests the existence of a feed-forward loop accelerating disease progression, in which BCR-ABL1 enhances its own mutation rate in a STAT5-ROS dependent manner. This model explains the increased occurrence of inhibitor-resistant BCR-ABL1 mutations in advanced disease stages driven and characterized by high STAT5 expression.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.